Drug-Induced Liver Injury in the Setting of a Nonprescription Supplement Containing Ivermectin and Fenbendazole (2026)

Peer-Reviewed Study · Hunter AE, Hansen M, Cerda-Smith C, Choi S, Pierson D · 2026

Hunter AE et al., 2026: 2026 case of severe cholestatic and hepatocellular injury attributed to a marketed non-prescription supplement containing ivermectin and fenbendazole sold for 'cancer and parasite detoxification'. It documents that these combination products now reach patients as supplements and cause DILI.

A man presented with progressive jaundice, fatigue, and right upper quadrant pain following prolonged use of a nonprescription supplement containing ivermectin and fenbendazole

Hunter AE et al., 2026: 2026 case of severe cholestatic and hepatocellular injury attributed to a marketed non-prescription supplement containing ivermectin and fenbendazole sold for 'cancer and parasite detoxification'. It documents that these combination products now reach patients as supplements and cause DILI. C5 liver case (combination product). Study type: single case report; N=1; United States (Duke University School of Medicine, Durham, NC). Dose: 'prolonged use' of a nonprescription supplement containing ivermectin and fenbendazole – the mg amounts sit in the full text and are not quoted here. Comparator: none. Viral, autoimmune and obstructive causes were excluded. Funder and declared conflicts: not in the PubMed record. Bearing SUPPORTS the claim that liver effects are documented; the injury here cannot be attributed to ivermectin alone because fenbendazole was co-ingested. Study type: case report.